Wockhardt Ltd
About
Wockhardt Limited is a global pharmaceutical and biotechnology company. The company was established in 1967 by Dr. Habil Khorakiwala, who also serves as the Chairman. Wockhardt is headquartered in Mumbai. The company’s products include branded and generic formulations, APIs, contract manufacturing and new drug development. Wockhardt is known for its inventions such as India's first automatic insulin delivery device (Wosulin Pen) and the introduction of Povidone Iodine (Betadine) with Mundi Pharma. Wockhardt's manufacturing facility is present in Chikalthana, Chhatrapati Sambhajinagar. The company operates through six super speciality tertiary care hospitals. Wockhardt’s credo "LIFE WINS” underscores their commitment to healthcare. The company’s global team is a multi-ethnic workforce of 8,600 Wockhardt associates from 21 different nationalities
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 2895 7.7% | 2689 -15.0% | 3163 -19.9% | 3950 36.1% | 2903 -20.5% | 3652 -5.9% | 3879 -6.7% | 4155 -9.4% | 4584 -0.3% | 4599 -7.4% | 4966 -15.9% | 5902 30.3% | 4530 17.9% | 3842 -17.7% | 4666 27.3% | 3666 - |
| Net Operating Income (INR Cr) | 2798 5.55% | 2651 -17.93% | 3230 19.28% | 2708 -4.78% | 2844 -20.24% | 3566 -9.43% | 3937 -1.94% | 4015 -9.85% | 4453 -0.63% | 4482 -7.22% | 4830 -13.89% | 5609 28.94% | 4351 15.97% | 3751 -16.67% | 4501 25.40% | 3590 35.25% |
| Profit (INR Cr) | -463 - | -559 - | -244 - | 686 - | -69 - | -195 - | -608 - | -196 - | 251 -38.1% | 405 -51.8% | 841 -47.3% | 1594 365.2% | 343 278.6% | 91 - | -1001 - | -139 - |
| Assets (INR Cr) | 6118 2.8% | 5950 -9.6% | 6584 1.0% | 6517 -2.5% | 6685 3.9% | 6433 -8.2% | 7011 -12.1% | 7973 14.1% | 6988 17.7% | 5939 4.6% | 5676 17.2% | 4845 0.2% | 4837 10.4% | 4381 -6.6% | 4689 -10.7% | 5253 - |
| Net Worth (INR Cr) | 3359 0.2% | 3354 -12.9% | 3849 14.0% | 3376 26.4% | 2672 -0.1% | 2675 -6.2% | 2852 -14.5% | 3337 -11.6% | 3775 10.5% | 3417 4.1% | 3283 36.5% | 2406 239.0% | 710 258.6% | 198 - | 3 -99.7% | 1018 -20.1% |
| Employee Cost (INR Cr) | 629 -1.3% | 637 -15.0% | 749 -1.8% | 763 2.7% | 743 -7.1% | 800 -14.6% | 937 -3.1% | 967 1.7% | 951 9.4% | 869 13.0% | 769 17.2% | 656 14.5% | 573 5.6% | 542 -26.2% | 735 16.3% | 632 - |
| Interest Cost (INR Cr) | 305 | 302 | 299 | 249 | 276 | 265 | 255 | 225 | 129 | 55 | 83 | 215 | 269 | 267 | 342 | 259 |
| Cash & Bank Balance (INR Cr) | 529 | 124 | 406 | 292 | 268 | 449 | 1082 | 1604 | 1478 | 1235 | 1126 | 1096 | 700 | 483 | 347 | 650 |
| Total Debt (INR Cr) | 2356 | 2184 | 2198 | 2674 | 3582 | 3141 | 3748 | 4160 | 2677 | 2010 | 1906 | 2070 | 3281 | 3390 | 4018 | 4235 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | - | - | - | 17.4% | - | - | - | - | 5.5% | 8.8% | 16.9% | 27.0% | 7.6% | 2.4% | - | - |
| Profit As % Of Assets | - | - | - | 10.5% | - | - | - | - | 3.6% | 6.8% | 14.8% | 32.9% | 7.1% | 2.1% | - | - |
| Profit As % Of Networth | - | - | - | 20.3% | - | - | - | - | 6.6% | 11.9% | 25.6% | 66.3% | 48.3% | 45.7% | - | - |
| Interest Cost to EBITDA % | 1220.0% | - | 260.0% | - | 231.7% | - | - | 1759.9% | 26.1% | 7.8% | 9.2% | 10.4% | 30.5% | 79.6% | - | 371.0% |
| Debt to Equity Ratio | 0.70 | 0.65 | 0.57 | 0.79 | 1.34 | 1.17 | 1.31 | 1.25 | 0.71 | 0.59 | 0.58 | 0.86 | 4.62 | 17.13 | - | 4.16 |
| RONW | - | - | - | 27.5% | - | - | - | - | 7.0% | 12.3% | 29.6% | 102.4% | 128.0% | - | - | - |
| ROCE | -0.9% | -0.5% | 1.2% | 13.0% | 0.5% | -1.4% | -1.3% | -0.9% | 6.8% | 11.1% | 18.8% | 42.7% | 28.6% | 21.0% | 0.0% | 12.5% |